 Home > Active Ingredient News > Antitumor Therapy > JNNP: A prospective study of cancer survival in patients with HuD antibody-related paraneoplastic neurological diseases

JNNP: A prospective study of cancer survival in patients with HuD antibody-related paraneoplastic neurological diseases

 Last Update: 2021-04-17
 Source: Internet
 Author: User

Tags

group 16

journal article example

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Paraneoplastic neurological diseases (PND) often appear before tumor detection and are accompanied by spontaneous tumor regression in a small number of patients, which suggests that the immune response to HuD (which may be mediated by cytotoxic T cells) may be helpful to patients.

immunity

From July 2012 to June 2015, we prospectively collected at Oxford University Hospital all Hu antibody positive serum samples as a routine diagnostic part of the test, through the British 152 acute hospital Trust Fund referral will.

Diagnostic Fund

103 patients were recruited.

Among Hu antibody-positive patients, the Hu antibody titer was higher than that of the 22/245 SCLC control group (p=0.

Kaplan-Meier survival curve

Most deaths are considered to be related to cancer (total deaths are 45/76; Hu-Ab/PND/SCLC patients are 34/49; Hu-Ab/PND/SCLC patients are 11/19), especially Hu-Ab/PND/SCLC patients with PND confined to the peripheral nervous system (20/29, 69%).

The median cancer survival (11.

The results of the study show that compared with small cell lung cancer patients without neurological diseases, the prognosis of Hu-Ab/PND/SCLC patients is generally moderate, and the incidence of limited-stage small cell lung cancer is higher.

Compared with small cell lung cancer patients without neurological diseases, the prognosis of Hu-Ab/PND/SCLC patients is generally moderate, and the incidence of limited-stage small cell lung cancer is higher.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.